We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
46 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IZERVAY avacincaptad pegol 2 mg/0.1 mL solution for injection vial.
-
Prescription medicine registrationActive ingredients: avacincaptad pegol.
-
Australian public assessment report (AusPar)Vyloy (zolbetuximab), in combination with fluoropyrimidine and platinum-containing chemotherapy, has been approved for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GOJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VYLOY zolbetuximab 100 mg vial powder for concentrate for solution for infusion.
-
Prescription medicine registrationActive ingredients: zolbetuximab.
-
Prescription medicine registrationActive ingredients: enfortumab vedotin.
-
Prescription medicine registrationActive ingredients: enzalutamide.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VEOZA fezolinetant 45 mg film coated tablet blister pack.
-
Australian public assessment report (AusPar)Veoza (fezolinetant) has been approved for the treatment of moderate to severe hot flashes associated with menopause
-
Prescription medicine decision summaryVeoza (fezolinetant) has been approved for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause.